SeaStar Medical (NASDAQ:ICU) Rating Increased to Hold at Wall Street Zen

by · The Markets Daily

Wall Street Zen upgraded shares of SeaStar Medical (NASDAQ:ICU – Free Report) from a sell rating to a hold rating in a research report report published on Saturday,Wall Street Zen reports.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of SeaStar Medical in a research note on Friday, July 17th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $8.00.

Check Out Our Latest Research Report on SeaStar Medical

SeaStar Medical Trading Up 1.1%

Shares of ICU opened at $3.54 on Friday. The company’s fifty day simple moving average is $3.39 and its 200 day simple moving average is $3.53. SeaStar Medical has a 1-year low of $2.07 and a 1-year high of $12.50. The company has a market cap of $15.61 million, a price-to-earnings ratio of -0.91 and a beta of -1.05.

SeaStar Medical (NASDAQ:ICU – Get Free Report) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.91) EPS for the quarter, beating analysts’ consensus estimates of ($0.97) by $0.06. The firm had revenue of $0.61 million during the quarter, compared to analysts’ expectations of $0.49 million. SeaStar Medical had a negative net margin of 795.51% and a negative return on equity of 162.75%. As a group, research analysts forecast that SeaStar Medical will post -3.66 earnings per share for the current year.

About SeaStar Medical

(Get Free Report)

SeaStar Medical Holding Corporation (NASDAQ: ICU) is a medical technology company focused on developing therapies that address excessive inflammation and immune-system activation in critically ill patients. The company’s approach is designed to target activated immune cells in the bloodstream, which can contribute to organ damage and complications associated with severe illness.

SeaStar Medical’s lead product is Quelimmune, formerly known as the Selective Cytopheretic Device (SCD). The extracorporeal blood-purification device is used with continuous kidney replacement therapy to selectively target pro-inflammatory cells while blood circulates outside the body.

See Also